Methyldopa/Hydrochlorothiazide Tablets Rx
Generic Name and Formulations:
Methyldopa, hydrochlorothiazide; 250mg/15mg, 250mg/25mg; tabs.
Various generic manufacturers
Indications for Methyldopa/Hydrochlorothiazide Tablets:
Titrate individual components. Initially one 250mg/15mg tab 2–3 times daily or one 250mg/25mg tab 2 times daily.
Active hepatic disease. Anuria. Sulfonamide allergy. History of methyldopa-associated liver dysfunction. Concomitant MAOIs.
History of hepatic dysfunction. Pheochromocytoma. Severe cerebrovascular or renal disease. SLE. Gout. Diabetes. Asthma. Edema. Dialysis. Postsympathectomy. Monitor blood, liver function, blood lipids, and electrolytes. Surgery. Pregnancy (Cat.C). Nursing mothers: not recommended.
MAOIs (see Contraindications). Alcohol, CNS depressants may increase orthostatic hypotension. May increase toxicity of diazoxide, digitalis and lithium. May antagonize oral hypoglycemics. Antagonized by NSAIDs, iron. May interfere with parathyroid tests.
Central alpha agonist + diuretic.
Hemolytic anemia, fever, jaundice, hepatic necrosis, granulocytopenia, fluid or electrolyte imbalance, blurred vision, sedation, headache, asthenia, orthostatic hypotension, bradycardia, GI upset, rash, nasal congestion, hyperprolactinemia, arthralgia, positive Coomb's test.
Formerly known under the brand name Aldoril.
Neurology Advisor Articles
- The Consequences of Compensation in Autism
- Fingolimod May Help Prevent Brain Volume Loss in Relapsing-Remitting Multiple Sclerosis
- Novel Therapy May Improve Symptoms in Early Huntington Disease
- Interaction of Alcohol, Smoking on Multiple Sclerosis Severity
- Demoralization Common in Patients With Parkinson Disease
- Multiple Sclerosis Guidelines: AAN's Recommendations for Initiating, Switching, Stopping Disease-Modifying Therapy
- Migraine a Common Comorbidity in Individuals With Sarcoidosis
- Cardiovascular Risk Factors and Development of Brain Atrophy in Multiple Sclerosis
- Association Between Multiple Sclerosis Relapses and Vaccinations
- Understanding Impulse Control Disorders in Parkinson Disease: Developments and Treatments